Envío mundial con seguimiento | Aprox. 9–14 días hábiles

Tu carrito

Tu carrito está vacío

Comenzar a explorar

Envío gratuito en pedidos superiores a €500.

Subtotal€0
Proceder al pago
LongevidadClínico temprano

LL-37

Investigación publicada y base de evidencia

LL-37 is the sole human cathelicidin antimicrobial peptide, a 37-residue amphipathic alpha-helical peptide released by proteolytic cleavage of the hCAP18 precursor encoded by the CAMP gene. It is expressed by neutrophils, monocytes and epithelial cells, transcriptionally induced by 1,25-dihydroxyvitamin D3, and acts through direct membrane permeabilisation of microbes, neutralisation of lipopolysaccharide, and receptor-mediated chemotaxis and immunomodulation. Its biological effect is strongly concentration- and context-dependent, and elevated LL-37 is implicated as a pathogenic driver in rosacea, psoriasis and atherosclerosis as well as a host-defence effector. The great majority of the literature is in vitro or animal work; human interventional data are limited to a small number of topical and oral formulations.

En resumen
  • LL-37 es un péptido antimicrobiano humano producido por células inmunitarias y epiteliales.
  • Estudios celulares y animales reportaron efectos antimicrobianos e inmunitarios.
  • Los ensayos humanos usaron solo formas tópicas u orales; el ensayo más grande fue negativo.

22 estudios · 13 desde 2023 · más reciente 2026

Estudios citados
22
Publicados en 2023+
13
Artículo más reciente
2026
Última revisión
oct 2026

Temas recurrentes en la literatura

  • antimicrobial and antibiofilm activity
  • vitamin D-driven CAMP gene induction
  • LPS neutralisation
  • chemotaxis via FPR2/FPRL1
  • wound healing and angiogenesis
  • rosacea and psoriasis inflammation
  • antiviral activity
  • neutrophil extracellular traps
  • atherosclerosis autoantigen
  • engineered LL-37 analogues and ceragenins

Identificadores del compuesto

CAS
154947-66-7
PubChem
16198951

Identidad química

Qué es LL-37, químicamente.

Fórmula molecular
C205H340N60O53
Peso molecular
4493 g/mol
Número CAS
154947-66-7
PubChem CID
16198951
También escrito como

ropocamptide, Cap-18, cathelicidin LL-37

Estas cifras provienen del registro PubChem para este compuesto y describen la base libre. El péptido liofilizado normalmente se suministra como sal de acetato o trifluoroacetato y contiene agua residual, por lo que la masa de polvo en un vial no es la misma cantidad que sugeriría el peso molecular anterior. La pureza cromatográfica en un certificado de análisis tampoco resuelve esa diferencia — cómo leer un certificado de análisis explica por qué.

La evidencia

22 estudios publicados.

Ordenados por solidez del diseño del estudio, luego por antigüedad. Cada entrada enlaza a su registro fuente para que el hallazgo pueda verificarse contra el artículo en lugar de tomarse bajo nuestra palabra.

  1. 01Revisión sistemática2026

    Cathelicidin antimicrobial peptides: current progress and future prospects in immunotherapy

    Ding A, et al. · Developmental and Comparative Immunology · Systematic review of cathelicidin structure, biology and clinical translation

    The review catalogued the molecular structure, cellular sources and mechanisms of cathelicidin peptides and their progress toward clinical application in infectious and non-infectious disease. The authors noted that limitations of current candidates constrain translation despite growing interest driven by antibiotic resistance.

  2. 02Clínico humano2026

    LL-37-ApoB-100 Complex Serves as a Biomarker of Coronary Artery Disease

    Fang Y, et al. · Arteriosclerosis, Thrombosis, and Vascular Biology · Observational case-control study, 1103 patients undergoing coronary angiography across two independent centres, with supporting surface plasmon resonance and Apoe-/- mouse work

    Circulating LL-37-ApoB-100 complex correlated with angiographic disease severity (Gensini score r = 0.60) and discriminated obstructive coronary artery disease with an AUC of 0.82. Elevated levels remained an independent predictor after adjustment for lipid and clinical measures (adjusted OR 6.51, 95% CI 4.34 to 9.77).

  3. 03Clínico humano2026

    Adaptive immune response to the autoantigen LL-37 differentiates atherosclerotic cardiovascular disease phenotypes

    Dimayuga PC, et al. · Clinical & Translational Immunology · Observational immunophenotyping study of PBMCs and plasma from patients with stable atherosclerotic cardiovascular disease after myocardial infarction, stroke or peripheral artery disease

    LL-37 provoked an increased CD4+CD25+CD134+ T-cell response in post-myocardial-infarction patients while CD8+ responses were reduced in peripheral artery disease. LL-37 IgG immune complexes were elevated across disease phenotypes and cross-reacted with native LDL only in post-infarction plasma.

  4. 04Clínico humano2023

    Efficacy and safety of Oral LL-37 against the Omicron BA.5.1.3 variant of SARS-COV-2: A randomized trial

    Zhao Y, et al. · Journal of Medical Virology · Open-label randomised placebo-controlled single-centre trial, 238 adult COVID-19 inpatients, recombinant LL-37 Lactococcus lactis oral formulation

    Oral LL-37 shortened SARS-CoV-2 RNA negative conversion time relative to placebo (9.80 +/- 2.67 versus 14.04 +/- 5.89 days, p < 0.01) when started within six days of confirmation. Benefit was concentrated in early treatment, with an adjusted hazard ratio of 6.28 (95% CI 3.63 to 10.85) versus later initiation.

  5. 05Clínico humano2023

    Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial

    Miranda E, et al. · Archives of Dermatological Research · Randomised double-blind placebo-controlled trial, mildly infected diabetic foot ulcers, topical LL-37 cream twice weekly for 4 weeks (NCT04098562)

    The granulation index increased more in the LL-37 arm at days 7, 14, 21 and 28 (p = 0.031, 0.009, 0.006 and 0.037). LL-37 cream did not significantly reduce IL-1alpha, TNF-alpha or aerobic bacterial colonisation compared with placebo.

  6. 06Clínico humano2021

    Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial

    Mahlapuu M, et al. · Wound Repair and Regeneration · Phase IIb double-blind randomised placebo-controlled trial (HEAL LL-37), 148 patients with hard-to-heal venous leg ulcers, topical LL-37 at 0.5 or 1.6 mg/mL

    Efficacy analysis across the full cohort found no significant improvement in healing with LL-37 versus placebo. A post-hoc subgroup with wounds of at least 10 cm2 showed improvement across several healing parameters, and the drug was well tolerated at both dose strengths.

  7. 07Clínico humano2020

    Preliminary evaluation of the safety and efficacy of oral human antimicrobial peptide LL-37 in the treatment of patients of COVID-19, a small-scale, single-arm, exploratory safety study

    Zhang H, et al. · medRxiv · single-arm exploratory safety study (medRxiv preprint), 11 patients with mild COVID-19 given oral cas001, a genetically modified Lactococcus lactis producing human LL-37, for 3 weeks

    None of the 11 patients reported adverse reactions or discomfort, and the authors described improvement in gastrointestinal symptoms with possible effects on systemic and respiratory symptoms. The authors stated that conclusions on clinical outcomes could not be reached from this uncontrolled study.

  8. 08Clínico humano2014

    Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial.

    Grönberg A, et al. · Wound Repair Regen · first-in-man randomized double-blind placebo-controlled trial, n=34 patients with hard-to-heal venous leg ulcers, 4 weeks treatment + 4 weeks follow-up

    Healing rate constants for the two lower LL-37 concentrations were about six- and threefold higher than placebo, with mean ulcer area reductions of 68% and 50%; the highest concentration did not differ from placebo. No local or systemic safety concerns were identified.

  9. 09Animal in vivo2026

    Serine protease HtrA promotes Campylobacter jejuni intestinal colonization through degrading antimicrobial peptide LL-37

    Li X, et al. · Science Advances · Campylobacter jejuni bacterial genetics with mouse intestinal colonisation experiments

    LL-37 exposure activated the regulator NssR, upregulating htrA, whose secreted protease cleaved LL-37 at the Ile20-Val21 site and abolished antimicrobial activity. A non-cleavable LL-37 variant showed enhanced antibacterial activity and promoted bacterial clearance in mice.

  10. 10Animal in vivo2026

    Immunomodulatory Effects of Poly-D,L-Lactic Acid on LL-37-Driven Rosacea-like Inflammation via Suppression of mTORC1 Signaling

    Byun KA, et al. · International Journal of Molecular Sciences · LL-37-injected mouse model of rosacea-like cutaneous inflammation

    LL-37 injection reduced IL-10 and pSTAT3 while increasing TLR2/KLK5/LL-37 amplification, NF-kappaB, VEGF and NLRP3 inflammasome signalling, reproducing rosacea-like disease. Poly-D,L-lactic acid partially restored the STAT3/DDIT4-AMPK pattern, suppressed mTORC1 and reduced lesion area.

  11. 11Animal in vivo2025

    A pilot study of healing critical-sized calvarial defects by LL-37-generated monoosteophils

    Le K, et al. · Frontiers in Bioengineering and Biotechnology · Critical-sized calvarial defect model using monoosteophils differentiated from monocytes by LL-37

    LL-37-generated monoosteophils formed intracellular hydroxyapatite-containing nodules confirmed by SEM/EDS and filled large calvarial defects in a pilot experiment. The authors reported that bone repair function required hydroxyapatite formation within the cells.

  12. 12Animal in vivo2024

    Cathelicidin LL-37 promotes wound healing in diabetic mice by regulating TFEB-dependent autophagy

    Xi L, et al. · Peptides · Diabetic mouse wound model with HaCaT keratinocyte experiments under high glucose

    LL-37 accelerated wound closure in diabetic mice, and the effect was reversed by the autophagy inhibitor 3-MA. Mechanistically LL-37 drove nuclear translocation of TFEB and upregulation of ATG5, ATG7 and beclin 1, and TFEB knockdown abolished the promotion of keratinocyte migration.

  13. 13Animal in vivo2007

    Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea.

    Yamasaki K, et al. · Nat Med · facial skin of rosacea patients vs controls plus mouse injection and gene-deletion models (Spink5, Camp)

    Rosacea patients had abnormally high facial cathelicidin with aberrantly processed peptide forms linked to increased stratum corneum tryptic enzyme; injecting these cathelicidin peptides into mouse skin increased inflammation, and cathelicidin was required for protease-driven inflammation in Camp-deleted mice.

  14. 14In vitro2026

    Human cathelicidin peptide LL-37 compacts nucleic acids and alters neutrophil extracellular trap structure

    Zielke C, et al. · Scientific Reports · Biophysical study of LL-37 with nucleic acids and isolated neutrophil extracellular traps

    LL-37 condensed double-stranded DNA into particles of roughly 150 nm through electrostatic interaction between its cationic side chains and the phosphodiester backbone, a process requiring the peptide's amphipathic alpha-helical structure. High LL-37 concentrations significantly reduced projected NET area.

  15. 15In vitro2026

    LL-37 Inhibits EV71 Infection by Upregulating STAC via the EGFR-ERK Signaling Pathway

    Zhang J, et al. · Viruses · Cell culture models of enterovirus 71 infection with transcriptomics and shRNA knockdown

    LL-37 suppressed enterovirus 71 protein expression and infectious titres, acting predominantly after viral entry. The effect was mediated by EGFR-ERK-dependent upregulation of the SH3 and cysteine-rich domain protein Stac, since Stac silencing enhanced infection and overexpression reduced it.

  16. 16In vitro2008

    Human host defense peptide LL-37 prevents bacterial biofilm formation

    Overhage J, et al. · Infection and Immunity · Pseudomonas aeruginosa biofilm assays with microarray transcriptomics

    LL-37 inhibited biofilm formation and disrupted pre-grown Pseudomonas aeruginosa biofilms at concentrations far below its minimum inhibitory concentration of 64 microgram/mL. It acted by reducing bacterial attachment, stimulating twitching motility and downregulating the Las and Rhl quorum-sensing systems.

  17. 17In vitro2007

    Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide.

    Lande R, et al. · Nature · human plasmacytoid dendritic cells and psoriatic skin samples

    LL37 bound self-DNA into aggregated, condensed structures that were delivered to and retained in early endosomes of plasmacytoid dendritic cells, triggering TLR9 and type I interferon production; the authors identified LL37 as the key factor driving pDC activation in psoriasis.

  18. 18In vitro2004

    Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression

    Wang TT, et al. · Journal of Immunology · Human keratinocytes, monocytes, neutrophils and cell lines

    The CAMP and defensin beta 2 genes were shown to contain consensus vitamin D response elements mediating 1,25(OH)2D3-dependent transcription, with synergistic induction by LPS in neutrophils. Treated cells secreted increased antimicrobial activity against pathogens including Pseudomonas aeruginosa.

  19. 19In vitro2000

    LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells

    De Yang, et al. · Journal of Experimental Medicine · Human monocytes, neutrophils and T cells plus FPRL1-transfected HEK293 cells

    LL-37 was chemotactic for human monocytes, neutrophils and T lymphocytes and induced calcium mobilisation in FPRL1-transfected cells, an effect cross-desensitised by an FPRL1-specific agonist. This established a receptor-mediated immunological role for LL-37 distinct from direct microbicidal killing.

  20. 20Revisión2026

    LL-37: Biological Mechanisms and Emerging Therapeutic Applications in Intestinal Disease

    Liu Q, et al. · Immunity, Inflammation and Disease · Narrative review of LL-37 in the intestinal immune axis

    The review described LL-37 as maintaining intestinal homeostasis through antibacterial, immunomodulatory and tissue-repair functions whose direction depends on peptide concentration, receptor binding, disease stage and local microenvironment. It set out the conditions under which LL-37 activity converts from protective to pathogenic in inflammatory bowel disease and colorectal cancer.

  21. 21Revisión2026

    Exploring the role of cathelicidin LL-37 and ceragenins in wound healing processes

    Łuckiewicz M, et al. · European Journal of Pharmacology · Narrative review of antimicrobial peptides and synthetic ceragenin analogues in wound healing

    The review summarised mechanisms by which LL-37 and ceragenins support healing, including antimicrobial action preventing infection and promotion of cell migration and proliferation. It framed these agents as candidates for chronic wound and hypertrophic scar management rather than as established therapies.

  22. 22Reporte de caso2018

    Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features.

    Dolkar T, et al. · J Cutan Pathol · single case, 63-year-old woman with stage IIIC melanoma in a phase 1 trial of intratumoral LL-37 (8 weekly injections)

    About 45 days after starting LL-37 injections the patient developed multiple verrucous papules and a vesiculo-bullous lesion; 11 of 12 biopsies showed a lichenoid infiltrate with eosinophils and atypical, keratoacanthoma-like squamous proliferation. All lesions resolved within 2 months of stopping therapy, while injected lesions had shrunk.

    Hallazgo de seguridad reportado. Intratumoral LL-37 was followed by widespread lichenoid, keratoacanthoma-like skin lesions that resolved after treatment stopped.

Limitaciones

Lo que esta evidencia no establece.

There is no approved LL-37 product and no human data on systemic administration; the only injectable human data come from intratumoral injection in a phase 1 melanoma trial, the controlled human trials use topical or oral formulations, and the largest of these, the phase IIb HEAL LL-37 venous leg ulcer trial, was negative on its primary analysis. LL-37 is simultaneously implicated as a pathogenic driver in rosacea, psoriasis and atherosclerosis, so its concentration- and context-dependent switch between protective and inflammatory behaviour is not adequately characterised, and human pharmacokinetics, dose-response and long-term safety are unestablished.

Preguntas comunes sobre la investigación.

What is LL-37?

LL-37 is the only human cathelicidin-derived antimicrobial peptide. It is cleaved from the precursor protein hCAP-18, which is stored in neutrophil granules and expressed by epithelial cells, and is named for its two leading leucine residues and 37-amino-acid length.

Is LL-37 an antibiotic?

It is described in the literature as a host-defence peptide with direct membrane-disrupting activity against bacteria, which is not the same as a clinical antibiotic. No LL-37 product is approved as an anti-infective anywhere, and the research material on this page is not supplied or intended for treating infection.

How does LL-37 differ from KPV?

Both appear in inflammation and barrier-tissue research, but they are structurally unrelated. LL-37 is a 37-amino-acid cationic helix derived from human cathelicidin and studied for membrane and host-defence activity; KPV is the tripeptide C-terminal fragment of alpha-MSH studied for melanocortin-pathway signalling.

Disponible en nuestro catálogo

Solo para fines de investigación. No apto para consumo humano, diagnóstico, tratamiento o prevención de ninguna condición. Nada en esta página constituye consejo médico, y ningún estudio resumido aquí debe leerse como una recomendación.